pembrolizumab

Open Access
Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer
AYUMU HOSOKAWA, RIN YAMADA, YUKIKO OTSUKI, HOTAKA TAMURA, AKIKO ICHIHARA, TSUYOSHI FUKUSHIMA and YOSHIHIRO KOMOHARA

Anticancer Research November 2025, 45 (11) 5069-5076; DOI: https://doi.org/10.21873/anticanres.17847
You have access
Pathological Complete Response in Locally-advanced MSI-H/dMMR Sigmoid Colon Cancer Treated With Pembrolizumab and Abdominal Reconstruction
MASASHI SHIMASAKI, YUKI KIYOZUMI, RYOTA OHMURA, KOZUE MATSUISHI, TOMO HORINOUCHI, TOSHIHIKO YUSA, MASAYO TSUKAMOTO, TAISUKE YAGI, TAKAYOSHI KAIDA, KOTA ARIMA, KENJI SHIMIZU, KENSUKE YAMAMURA, KENSUKE SAKATA, YASUO SAKAMOTO, HISANOBU ODA, TAKIHIRO KAMIO and KATSUNORI IMAI

Anticancer Research November 2025, 45 (11) 5239-5246; DOI: https://doi.org/10.21873/anticanres.17864
You have access
Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma
DIMITRI ANZELLINI, MARCO LODDO and SERGIO DEL BIANCO

Anticancer Research September 2025, 45 (9) 3809-3816; DOI: https://doi.org/10.21873/anticanres.17740
You have access
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
TOMOHIRO MATSUO, YASUYOSHI MIYATA, JUNKI HARADA, ITSUHO ITOH, TSUYOSHI MATSUDA, AKIHIRO ASAI, TSUBASA KONDO, HIROKI KURATA, SUZUNA SAKAI, HIDENORI ITOH, KENSUKE MITSUNARI and RYOICHI IMAMURA

Anticancer Research June 2025, 45 (6) 2563-2573; DOI: https://doi.org/10.21873/anticanres.17628
You have access
Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab
KOHEI HAGIWARA, TAKASHI MATSUKI, TAKURO OKADA, CHIHIRO FUSHIMI, TAKAHITO KONDO, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, KIYOAKI TSUKAHARA, TATSUO MASUBUCHI, YUICHIRO TADA, KAHO MOMIYAMA, RYOHEI YAGUCHI, NOBUHIKO ORIDATE, GO OMURA and TAKU YAMASHITA

Anticancer Research September 2024, 44 (9) 4057-4072; DOI: https://doi.org/10.21873/anticanres.17235
You have access
Pathological Complete Response to Liver Metastasis With Pembrolizumab in a Previously Treated Patient With Microsatellite Instability-high Colorectal Cancer
AYUMU HOSOKAWA, HOTAKA TAMURA, AKIKO ICHIHARA, NAOYA IMAMURA, KENGO KAI, TSUYOSHI FUKUSHIMA, ATSUSHI NANASHIMA and YOSHIHIRO KOMOHARA

Anticancer Research September 2024, 44 (9) 4119-4125; DOI: https://doi.org/10.21873/anticanres.17241
Open Access
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
AKINORI MINATO, NOBUKI FURUBAYASHI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOOHYUN SONG, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, KENTARO KUROIWA, NARIHITO SEKI, IKKO TOMISAKI, MOTONOBU NAKAMURA, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research August 2024, 44 (8) 3419-3426; DOI: https://doi.org/10.21873/anticanres.17162
You have access
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer
HIROTAKA FUCHIZAWA, KIYOHIRO ANDO, NORIKO MOTOI, TOSHIHIKO IIZUKA, MASAHARU INOUE, KOUKI MITANI, YUTA SANO, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, YOH MATSUOKA, TAKEHIKO KAMIJO and YUKIO KAGEYAMA

Anticancer Research May 2024, 44 (5) 1925-1930; DOI: https://doi.org/10.21873/anticanres.16994
You have access
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy
MINEHIKO INOMATA, SHUHEI MINATOYAMA, NAOKI TAKATA, KANA HAYASHI, TAKAHIRO HIRAI, ZENTA SETO, KOTARO TOKUI, CHIHIRO TAKA, SEISUKE OKAZAWA, KENTA KAMBARA, SHINGO IMANISHI, TOSHIRO MIWA, KEI MATSUYAMA, RYUJI HAYASHI, SHOKO MATSUI and KAZUYUKI TOBE

Anticancer Research March 2024, 44 (3) 1241-1245; DOI: https://doi.org/10.21873/anticanres.16920
You have access
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
TETSUYA SHINDO, KOHEI HASHIMOTO, ATSUSHI TAKAHASHI, SHINTARO MIYAMOTO, YASUHARU KUNISHIMA, SHUNSUKE SATO, FUMIMASA FUKUTA, YOSHIKI HIYAMA, AKIO TAKAYANAGI, RYUICHI KATO, ATSUSHI WANIFUCHI, YOHEI UEKI, MANABU OKADA, HIDEKI ADACHI, KO KOBAYASHI, TOSHIAKI TANAKA and NAOYA MASUMORI; on behalf of the Sapporo Medical University Urologic Oncology Consortium

Anticancer Research March 2024, 44 (3) 1271-1279; DOI: https://doi.org/10.21873/anticanres.16922

Main menu

User menu

Search

pembrolizumab

Pages